NCT02762370View on ClinicalTrials.gov

Study to Assess the Effects of FX006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

October 31, 2016

Study Completion Date

November 30, 2016

Conditions
Osteoarthritis of the KneeType 2 Diabetes Mellitus
Interventions
DRUG

FX006 32 mg

Single 5 mL IA injection

DRUG

TCA IR 40 mg

Single 1 mL IA injection

Trial Locations (8)

16635

Duncansville

29464

Mt. Pleasant

37938

Knoxville

75231

Dallas

78258

San Antonio

91606

North Hollywood

92020

El Cajon

92801

Anaheim

Sponsors
All Listed Sponsors
lead

Pacira Pharmaceuticals, Inc

INDUSTRY

NCT02762370 - Study to Assess the Effects of FX006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes | Biotech Hunter | Biotech Hunter